WallStSmart

Alcon AG (ALC)vsAtriCure Inc (ATRC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 1807% more annual revenue ($10.86B vs $569.62M). ALC leads profitability with a 5.9% profit margin vs 1.9%. ALC appears more attractively valued with a PEG of 1.27. ALC earns a higher WallStSmart Score of 51/100 (C-).

ALC

Buy

51

out of 100

Grade: C-

Growth: 4.7Profit: 4.5Value: 3.3Quality: 6.8
Piotroski: 3/9

ATRC

Hold

35

out of 100

Grade: F

Growth: 6.0Profit: 4.0Value: 4.7Quality: 8.5
Piotroski: 5/9Altman Z: 2.17
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-22.0%)

Margin of Safety

-22.0%

Fair Value

$65.08

Current Price

$66.03

$0.95 premium

UndervaluedFair: $65.08Overvalued
ATRCUndervalued (+56.0%)

Margin of Safety

+56.0%

Fair Value

$74.75

Current Price

$54.54

$20.21 discount

UndervaluedFair: $74.75Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 9.5/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

ATRC1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

Areas to Watch

ALC4 concerns · Avg: 2.8/10
Return on EquityProfitability
3.8%3/10

ROE of 3.8% — below average capital efficiency

Profit MarginProfitability
5.9%3/10

5.9% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
53.8x2/10

Premium valuation, high expectations priced in

ATRC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
1.9%3/10

1.9% margin — thin

PEG RatioValuation
10.002/10

Expensive relative to growth rate

P/E RatioValuation
255.9x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Price/Book, Debt/Equity. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bull Case : ATRC

The strongest argument for ATRC centers on Debt/Equity. Revenue growth of 12.8% demonstrates continued momentum.

Bear Case : ALC

The primary concerns for ALC are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 53.8x leaves little room for execution misses.

Bear Case : ATRC

The primary concerns for ATRC are EPS Growth, Profit Margin, PEG Ratio. A P/E of 255.9x leaves little room for execution misses. Thin 1.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

ATRC carries more volatility with a beta of 1.26 — expect wider price swings.

ATRC is growing revenue faster at 12.8% — sustainability is the question.

ALC generates stronger free cash flow (414M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ALC scores higher overall (51/100 vs 35/100). ATRC offers better value entry with a 56.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

AtriCure Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. The company is headquartered in Mason, Ohio.

Want to dig deeper into these stocks?